Advancing a Differentiated Treatment Option
Molecular Templates’ lead compound, MT-3724, is a first generation ETB that targets CD20, a B-cell marker that is expressed in 90 percent of B-cell non-Hodgkin’s lymphoma (NHL).
Molecular Templates’ lead compound, MT-3724, is a first generation ETB that targets CD20, a B-cell marker that is expressed in 90 percent of B-cell non-Hodgkin’s lymphoma (NHL).
Program | Partner | Indication (Target) | Preclinical | Phase 1 | Phase 2 | Phase 3 | Next Stage |
---|---|---|---|---|---|---|---|
MT-3724 |
![]() |
DLBCL monotherapy (CD20) |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
![]() |
DLBCL combination with GEMOX (CD20) |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
||
![]() |
DLBCL combination with Lenalidomide (CD20) |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type of non-Hodgkin lymphoma (NHL) in the U.S. and worldwide. This aggressive, fast-growing NHL affects B-lymphocytes, a type of white blood cell that creates antibodies to fight infections.
People in the U.S. expected to be diagnosed with NHL in 20201.
Estimated number of people who will die from the disease in 20201.
Radiation, chemotherapy +/- antibody treatment (Rituxan®), CAR-T, and stem cell transplant.
1 American Cancer Society. Accessed from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html on April 27, 2020.
To learn more about the MT-3724 candidate, explore our research publications.
View Posters & Presentations